It’s all upside now. All bad news has been accounted for. All cost has been expensed and all expectations(for csl112) have been flattened . If any benefit can be found for a subset of patients it is pure upside.
meanwhile all csl forecasts have always, and continue to, exclude any contribution. .
Ann: Top-line Results from the Phase 3 AEGIS-II Trial, page-23
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$294.88 |
Change
1.180(0.40%) |
Mkt cap ! $142.5B | |||
| Open | High | Low | Value | Volume |
| $294.99 | $296.49 | $293.82 | $249.0M | 844.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 347 | $294.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $294.89 | 956 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |